The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

FDA approves Dupixent for treating bullous pemphigoid in adults, showing significant improvements in disease management.

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent (dupilumab), for the treatment of adult patients with bullous pemphigoid (BP ...

Retinal diseases articles from across Nature Portfolio Retinopathy of prematurity Latest Research and Reviews ...